SEC Form 10-Q Summary
Filing entity: NeuroBo Pharmaceuticals, Inc. The request metadata identifies Metavia Inc., but the supplied filing is NeuroBo Pharmaceuticals, Inc. Form 10-Q, filed August 16, 2021, for the quarterly and six-month periods ended June 30, 2021. The financial statements are unaudited.
Business Context and Reporting Period
NeuroBo is a clinical-stage biotechnology company with four therapeutic programs: ANA001 for COVID-19, NB-01 for painful diabetic neuropathy and other neuropathic conditions, NB-02 for neurodegenerative disease, and Gemcabene for cardiometabolic and potential COVID-19 indications. The company has not generated product revenue and operates as a single therapeutic-development segment.
- ANA001 was in a 60-subject Phase 2 COVID-19 trial; management expected completion in the fourth quarter of 2021.
- NB-01 Phase 3 activities were halted and related CRO arrangements terminated.
- NB-02 development and first human trials were postponed, with possible activity targeted for the second half of 2021, subject to funding and market conditions.
- Gemcabene remained subject to a partial FDA clinical hold, while the company evaluated additional indications.
Financial Results and Key Metrics
| Metric | Three Months Ended June 30, 2021 | Three Months Ended June 30, 2020 | Six Months Ended June 30, 2021 | Six Months Ended June 30, 2020 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $2.0 million | $0.7 million | $3.2 million | $2.8 million |
| General and administrative expense | $1.9 million | $1.7 million | $4.1 million | $4.3 million |
| Total operating expense | $3.9 million | $2.4 million | $7.3 million | $7.1 million |
| Net loss | $3.9 million | $2.4 million | $7.2 million | $7.1 million |
| Net loss per share | $0.18 | $0.15 | $0.33 | $0.44 |
| Net cash used in operating activities | Not presented | Not presented | $9.7 million | $6.5 million |
The company had no meaningful revenue or operating margin because it remains pre-commercial and loss-making. Cash was $9.5 million at June 30, 2021, compared with $10.1 million at December 31, 2020. Total assets were $10.7 million and total liabilities were $1.2 million. Stockholders’ equity was $9.5 million, and accumulated deficit was $73.8 million.
The company had no conventional debt disclosed. Lease liabilities totaled $83,000, consisting of $25,000 current and $58,000 long-term obligations. Cash provided by financing activities was $9.2 million, primarily from a January 2021 private placement.
Material Changes Versus the Prior Comparable Period
- Second-quarter research and development expense increased $1.3 million, primarily due to increased development activity, including ANA001.
- Second-quarter total operating expense increased $1.5 million, and net loss increased $1.5 million.
- Six-month research and development expense increased $0.3 million, while general and administrative expense decreased $0.2 million.
- Six-month operating cash use increased to $9.7 million from $6.5 million, partly because of payments associated with the 2020 ANA merger and the timing of vendor invoices.
- January 2021 financing generated $10.0 million of gross proceeds through the issuance of 2.5 million common shares and warrants to purchase 2.5 million additional shares. Net financing proceeds were approximately $9.1 million after issuance costs.
- Shares outstanding increased to 22.3 million at June 30, 2021 from 19.7 million at December 31, 2020. Warrants outstanding increased to approximately 2.6 million, primarily from the January financing.
Guidance, Outlook, Risks, and Unusual Items
Management stated that existing cash was expected to fund operations into the first quarter of 2022 at the then-current level of scientific activity, with further cost reductions potentially extending the operating period into the second quarter of 2022. Additional financing was required, but no financing commitments existed at the filing date.
The financial statements disclose substantial doubt about the company’s ability to continue as a going concern. Management expects continuing net losses and negative operating cash flow and may seek equity or debt financing, collaborations, licenses, or other funding. Additional equity could dilute shareholders, while debt financing could impose restrictive covenants.
- COVID-19 could disrupt clinical trials, suppliers, contract research organizations, service providers, capital markets, and the broader economy.
- ANA001 development, regulatory approval, patient enrollment, clinical efficacy, and safety remain uncertain.
- NB-02 may require additional funding or a strategic partner before clinical activity can resume.
- Gemcabene remains on partial clinical hold and has potential milestone, royalty, and contingent-value-right obligations if development or licensing milestones are achieved.
- Potential future payments include substantial ANA merger and license milestones, but no related liabilities were recorded because achievement and funding were not considered probable.
- The company reported ineffective disclosure controls as of June 30, 2021 because of material weaknesses in accounting for clinical trial costs and mergers and acquisitions. Remediation was in progress but not complete.
- An August 13, 2021 release agreement with the chief operating officer provides for $125,000 of payments, subject to applicable conditions, plus certain health insurance costs following termination.
Important Facts for Investors to Verify
- Confirm the filing entity and ticker: the supplied document identifies NeuroBo Pharmaceuticals, Inc. and Nasdaq ticker NRBO, not Metavia Inc.
- Assess whether subsequent financing was completed before cash was expected to be exhausted in early 2022.
- Track ANA001 Phase 2 results, regulatory interactions, and any transition to later-stage trials.
- Determine whether NB-02 clinical development resumed and whether a strategic partnership was established.
- Monitor the FDA partial clinical hold and development strategy for Gemcabene.
- Review dilution from the 2.5 million warrants issued in the January 2021 financing and other outstanding equity awards.
- Follow remediation of the material weaknesses in clinical-trial accruals and merger-accounting controls.
- Evaluate the going-concern disclosure, accumulated deficit, operating cash burn, and the company’s ability to obtain additional capital.